DS
PTCT icon

David Shaw’s PTC Therapeutics PTCT Stock Holding History

David Shaw’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-54,000
Closed -$1.82M – 3920
2018
Q2 		$1.82M Sell
54,000
-1,800
-3% -$56.1K ﹤0.01% 2293
2018
Q1 		$1.51M Buy
+55,800
New +$1.41M ﹤0.01% 2228

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

David Shaw's PTCT Position: Q2 2026 in Review

David Shaw reduced its PTC Therapeutics (PTCT) stake by 5.6% in Q2 2026, selling an estimated $6.6M and leaving 1,548,919 shares worth $126M. The position accounts for 0.06% of the portfolio, ranked #364.

David Shaw first reported a position in PTCT in Q2 2014 and has held it in 45 quarters since. The position peaked at $133M in Q3 2025. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • David Shaw held 1,548,919 shares of PTC Therapeutics worth $126M as of Q2 2026.
  • David Shaw sold 91,462 PTC Therapeutics shares in Q2 2026, an estimated $6.6M.
  • PTC Therapeutics made up 0.06% of David Shaw's portfolio in Q2 2026, its #364 holding.
  • David Shaw first reported a position in PTC Therapeutics in Q2 2014 and has held it in 45 quarters since.
  • David Shaw's PTC Therapeutics position peaked at $133M in Q3 2025.
  • 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.